Market Overview - The Hong Kong stock market indices experienced a decline, with the Hang Seng Index falling by 1.01% to 26,439.68 points, the Hang Seng Tech Index down by 1.65%, and the National Enterprises Index decreasing by 1.11% [1][9]. Technology Sector - Technology stocks faced widespread losses, with Alibaba dropping over 4%, Bilibili down more than 3%, and Kuaishou, NetEase, and Meituan each declining by over 2% [1][9]. Biopharmaceutical Sector - The biopharmaceutical sector continued its upward trend, highlighted by Kangfang Biopharmaceutical's stock rising over 6%. The company announced an important update regarding its PD-1/VEGF bispecific antibody, which has shown statistically significant and clinically meaningful benefits in treating advanced non-squamous non-small cell lung cancer [2][11]. Metals Sector - The metals sector showed strength, with Luoyang Molybdenum rising over 5%. Citigroup raised its short-term copper price target to $14,000 per ton, although it warned that the price increase may be nearing its peak [5][14]. Oil Sector - Oil stocks weakened, with PetroChina falling over 3%. This decline follows an announcement regarding the transfer of 30 to 50 million barrels of oil from the Venezuelan interim government to the U.S., which will be sold at market prices [5][16]. Automotive Sector - The automotive sector saw significant declines, with NIO dropping over 3%. Reports indicate that the Chinese auto market may experience a 7% decline in sales in 2026, marking the first anticipated annual drop since 2020. A price war has begun, involving over 76 models from various manufacturers [6][16].

Core Viewpoint - Kangfang Biopharma (09926) experienced a significant stock increase of 6.15%, reaching HKD 127.8, with a trading volume of HKD 789 million, following the approval of an important update to the product label of its innovative PD-1/VEGF bispecific antibody, Ivosidenib (brand name: Yidafang) by the National Medical Products Administration [1] Group 1 - The update includes final analysis data from the AK112-301/HARMONi-A study, demonstrating statistically significant and clinically meaningful dual benefits in progression-free survival (PFS) and overall survival (OS) for Ivosidenib in treating locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR-TKI therapy [1] - The HARMONi-A study is noted as the first global Phase III clinical trial in the EGFR-TKI resistant nsq-NSCLC treatment field to achieve clinically meaningful and statistically significant benefits in both PFS and OS endpoints [1] - This trial is also recognized as the first randomized, double-blind Phase III clinical trial to achieve dual positive results in both PFS and OS, reaffirming the groundbreaking clinical value of Ivosidenib as the world's first tumor immune + anti-angiogenesis mechanism bispecific antibody [1]

Core Viewpoint - Kangfang Biopharma (09926) has seen a stock increase of over 6%, currently trading at 127.8 HKD with a transaction volume of 789 million HKD, following the approval of a significant update to the product label of its innovative PD-1/VEGF bispecific antibody, Ivosidenib (brand name: Yidafang) by the National Medical Products Administration [1] Group 1 - The update includes final analysis data from the AK112-301/HARMONi-A study, demonstrating statistically significant and clinically meaningful dual benefits in progression-free survival (PFS) and overall survival (OS) for Ivosidenib in treating locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR-TKI therapy [1] - The HARMONi-A study is the first global Phase III clinical trial in the EGFR-TKI resistant nsq-NSCLC treatment field to achieve clinically meaningful and statistically significant benefits in both PFS and OS endpoints [1] - This trial is also the first randomized, double-blind Phase III clinical trial to achieve dual positive results in PFS and OS, reaffirming the groundbreaking clinical value of Ivosidenib as the world's first tumor immune + anti-angiogenesis mechanism bispecific antibody [1]

Core Viewpoint - Kangfang Biopharma (09926) has seen a significant stock price increase, reaching a new historical high, driven by the announcement of its innovative PD-1/VEGF bispecific antibody drug, Ivosidenib, entering a pivotal Phase III clinical trial for treating advanced non-small cell lung cancer (NSCLC) [1] Group 1: Company Developments - Kangfang Biopharma's Ivosidenib, a globally first PD-1/VEGF bispecific antibody, has commenced its first patient dosing in a pivotal Phase III clinical study (AK112-305/HARMONi-8A) for patients with locally advanced or metastatic NSCLC who have failed prior PD-1/L1 inhibitors and platinum-based chemotherapy [1] - This marks the seventh Phase III study for Ivosidenib in the lung cancer field, with three of these being international multicenter registrations [1] - Ivosidenib has achieved comprehensive coverage of core indications in the NSCLC field, positioning the company to potentially reshape the overall treatment landscape for advanced NSCLC [1] Group 2: Strategic Importance - Ivosidenib serves as a cornerstone drug in the company's "IO+ADC" 2.0 strategy, focusing on core immuno-oncology indications with a series of ongoing Phase III and Phase II clinical trials [1]

Core Insights - The article discusses the positive results of a Phase III clinical trial (AK112-306/HARMONi-6) for the dual-specific antibody drug Iwosimab (PD-1/VEGF) in treating advanced squamous non-small cell lung cancer (sq-NSCLC) [1][2] - The trial demonstrated a statistically significant improvement in progression-free survival (PFS) compared to the control group, indicating a major clinical benefit [1][2] - Iwosimab is positioned to become a new standard treatment option in the NSCLC field, enhancing the clinical benefits of immunotherapy [2] Group 1: Clinical Trial Results - The HARMONi-6 trial included 532 participants, with approximately 63% having central squamous cell carcinoma, aligning with real-world patient distribution [1][2] - In the intention-to-treat population, the Iwosimab plus chemotherapy group showed a decisive positive result in PFS compared to the control group [1] - The safety profile of Iwosimab was favorable, with no new safety signals identified, and the incidence of treatment-related severe adverse events was similar to the control group [1] Group 2: Drug Development and Market Position - Iwosimab is the first PD-1/VEGF dual-specific tumor immunotherapy drug developed by the company, expected to receive NMPA approval for use in advanced EGFR-mutant NSCLC by May 2024 [3] - The drug is currently involved in 12 ongoing Phase III clinical trials, including three international multi-center studies [3] - Iwosimab is being tested for a total of 18 indications, covering various cancers such as lung cancer, biliary cancer, head and neck squamous cancer, triple-negative breast cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma [3]